[1]羡微微,刘桂清△.沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究[J].陕西医学杂志,2020,49(10):1306-1309.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.028]
　XIAN Weiwei,LIU Guiqing..Effect of sacubitril/valsartan on plasma norepinephrine and serum cardiac troponin I levels in patients with heart failure with reduced ejection fraction[J].,2020,49(10):1306-1309.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.028]
点击复制

沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1306-1309
栏目:
临床研究
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of sacubitril/valsartan on plasma norepinephrine and serum cardiac troponin I levels in patients with heart failure with reduced ejection fraction
作者:
羡微微1; 刘桂清2△
1.锦州医科大学齐齐哈尔医学院附属第一医院研究生培养基地(齐齐哈尔 161041); 2.齐齐哈尔医学院附属第一医院(齐齐哈尔161041)
Author(s):
XIAN Weiwei; LIU Guiqing.
Graduate Training Base of the First Affiliated Hospital of Qiqihar Medical College,Jinzhou Medical University(Qiqihar 161041)
关键词:
射血分数降低性心衰;  沙库巴曲缬沙坦;  去甲肾上腺素;  心肌肌钙蛋白I;  心脏不良事件;  不良反应
Keywords:
Heart failure with reduced ejection fraction;  Sacubitril valsartan;  Noradrenaline;  Cardiac troponin I;  Adverse cardiac events;  Adverse reaction
分类号:
R541.6
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.028
文献标志码:
A
摘要:
目的:探究沙库巴曲缬沙坦对射血分数降低性心衰(HFREF)患者血浆去甲肾上腺素(NE)和血清心肌肌钙蛋白I(cTnI)水平的影响。方法:将56例HFREF患者纳入研究。将其以随机数字表法分为试验组(26例)和对照组(30例)。两组均予以常规抗心衰治疗。在此基础上对照组增用盐酸贝那普利治疗,试验组采用沙库巴曲缬沙坦治疗。对所有受试者均进行为期6个月的随访观察,比较治疗前以及治疗后1个月两组血浆NE以及血清cTnI水平,治疗前以及治疗后6个月的心功能指标变化情况,6个月内再次住院次数以及累计住院时间,不良反应发生情况。结果:治疗后试验组血浆NE与血清cTnI水平均低于对照组(均P<0.05)。治疗后试验组左室射血分数(LVEF)高于对照组,而左心房内径(LA)、左心室舒张末期内径(LVEDD)低于对照组(均P<0.05)。试验组住院次数以及累计住院时间均少于对照组(均P<0.05)。试验组及对照组在各项不良反应发生率方面对比差异无统计学意义(均P>0.05)。结论:沙库巴曲缬沙坦对HFREF患者血浆NE和血清cTnI水平均有显著的改善作用,同时有利于促进患者心功能的改善,降低不良反应发生风险,减少再次住院次数以及累计住院时间。
Abstract:
Objective:To study the effect of sacubitril/valsartan on plasma norepinephrine(NE)and serum cardiac troponin I(cTnI)levels in patients with heart failure with reduced ejection fraction(HFREF).Methods:56 patients with HFREF were included in the study.They were divided into experimental group(26 cases)and control group(30 cases)by random number table method.Both groups received routine anti-heart failure treatment.On this basis,the control group was treated with benazepril hydrochloride,and the experimental group was treated with sacubitril/valsartan.All subjects were followed up for 6 months to compare the plasma NE and serum cTnI levels of the two groups before and 1 month after treatment,the changes in cardiac function indicators before and 6 months after treatment,the number of rehospitalization and the cumulative length of hospital stay within 6 months,and the incidence of adverse reactions.Results:After treatment,the serum levels of NE and cTnI in the experimental group were lower than those in the control group(All P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the experimental group was higher than that of the control group,while the left atrial diameter(LA)and left ventricular end-diastolic diameter(LVEDD)were lower than those of the control group(all P<0.05).The hospitalization frequency and cumulative hospitalization time in the experimental group were lower than those in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(all P>0.05).Conclusion:Sacubitril/valsartan can significantly improve the levels of plasma NE and serum cTnI in HFREF patients,and promote the improvement of cardiac function,and reduce the risk of adverse reactions,and reduce the number of rehospitalization and the cumulative length of hospital stay.

参考文献/References:

[1] Milton P.Who Should deliver medical therapy for patients with chronic heart failure?An immediate call for action to implement a community-based collaborative solution[J].Circulation Heart Failure,2017,10(8):4332-4333.
[2] De Vecchis C,Ariano G,Di BG,et al.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction:a retrospective cohort study[J].Herz,2018,44(13):1-8.
[3] 蒋松辰,高尚远,谢发江,等.沙库巴曲/缬沙坦对心肌肥厚兔半乳糖凝集素-3以及基质金属蛋白酶-9表达的影响[J].海南医学院学报,2019,25(8):561-565.
[4] 魏云杰,张 密,许海军,等.沙库巴曲缬沙坦治疗高龄射血分数降低心力衰竭患者的临床疗效研究[J].实用心脑肺血管病杂志,2018,26(7):17-20.
[5] 张洪颖,石 可,王绍久,等.《中国心力衰竭诊断和治疗指南2018》亮点解读[J].中国血液流变学杂志,2019,29(1):124-126.
[6] 孙 涛,闫继锋.比索洛尔联合沙库巴曲缬沙坦在慢性心力衰竭中的应用[J].重庆医学,2020,49(4):610-613.
[7] Solomon SD,Rizkala AR,Gong J,et al.Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction:rationale and design of the PARAGON-HF trial[J].JACC Heart Fail,2017,5(7):471-472.
[8] 邵夏炎,杨贝贝,刘洪智,等.沙库巴曲缬沙坦在射血分数降低的心力衰竭患者中的真实世界使用情况分析[J].实用临床医药杂志,2020,24(2):22-25.
[9] 王海燕,姜卫星,田 丽,等.沙库巴曲缬沙坦对急性前壁ST段抬高型心肌梗死PCI术后心力衰竭患者心功能的影响[J].河北医科大学学报,2020,41(3):254-258.
[10] 李 玮,穆少丽.冻干重组人脑利钠肽对缺血性心肌病合并心力衰竭患者神经内分泌激素及心室重构的影响[J].广西医科大学学报,2018,35(7):947-951.
[11] 康玲玲.厄贝沙坦联合胺碘酮治疗心力衰竭合并房颤的疗效及其对心功能、血浆Ang-Ⅱ、NE及BNP水平的影响[J].心血管康复医学杂志,2019,28(6):70-74.
[12] 李建设.慢性心力衰竭病人血清BNP、cTnI及心肌酶谱水平变化与心功能的关系探讨[J].中西医结合心脑血管病杂志,2017,15(16):2069-2071.
[13] 张凌云,王祖海,曲 伟,等.急性冠脉综合征患者血浆脂蛋白相关磷脂酶A2、C反应蛋白、肌钙蛋白I的变化及意义[J].中国基层医药,2018,25(14):1805-1810.
[14] 戴雯莉,吴翔宇,王 苏,等.沙库巴曲缬沙坦治疗慢性充血性心力衰竭患者的临床研究[J].中国医药,2019,14(9):1297-1301.
[15] 王 毅,杨 征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,48(4):470-472.
[16] 李海良,张克清.参芪复脉汤联合西药治疗慢性心衰疗效及对患者心功能的影响[J].陕西中医,2019,40(2):163-166.

相似文献/References:

[1]刘 哲,刘易婷,王 晶.沙库巴曲缬沙坦联合达格列净治疗2型糖尿病合并心力衰竭临床疗效观察[J].陕西医学杂志,2022,51(3):355.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.021]
　LIU Zhe,LIU Yiting,WANG Jing.Clinical efficacy of sacubitril/valsartan combined with dapagliflozin in treatment of type 2 diabetes mellitus complicated with heart failure[J].,2022,51(10):355.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.021]
[2]马红红,张启龙,刘娜娜,等.沙库巴曲缬沙坦对原发性高血压的治疗效果及机制研究[J].陕西医学杂志,2023,52(10):1384.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.022]
　MA Honghong,ZHANG Qilong,LIU Nana,et al.Therapeutic effect and mechanism of sacubitril/valsartan in patients with essential hypertension[J].,2023,52(10):1384.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.022]
[3]郝亚逢,张利峰,王学智,等.99mTc-MIBI门控心肌灌注显像对行沙库巴曲缬沙坦治疗的冠心病患者心肌血流灌注及心功能的评估价值[J].陕西医学杂志,2024,(4):514.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.017]
　HAO Yafeng,ZHANG Lifeng,WANG Xuezhi,et al.Evaluation value of 99mTc MIBI GMPI on myocardial blood flow perfusion and cardiac function in patients with coronary heart disease undergoing sacubarta valsartan treatment[J].,2024,(10):514.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.017]
[4]王丽辉,徐 佳,姜 晶.沙库巴曲缬沙坦联合螺内酯治疗慢性射血分数降低的心力衰竭临床价值研究[J].陕西医学杂志,2024,(5):675.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
　WANG Lihui,XU Jia,JIANG Jing.Value of sacubitril/valsartan combined with spironolactone in the treatment of chronic heart failure with reduced ejection fraction[J].,2024,(10):675.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
[5]赵亚男,解 琪,贾文旋,等.沙库巴曲缬沙坦联合托伐普坦治疗肺动脉高压所致右心衰竭疗效观察[J].陕西医学杂志,2024,(12):1680.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]
　ZHAO Yanan,XIE Qi,JIA Wenxuan,et al.Efficacy of sacubitril/valsartan combined with tolvaptan in treatment of pulmonary arterial hypertension-induced right heart failure[J].,2024,(10):1680.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]

更新日期/Last Update: 2020-10-10